Sionna Therapeutics, Inc Common Stock

Yahoo Finance • 8 days ago

ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch

On February 17, 2026, ENAVATE Sciences GP, LLC disclosed a buy of 157,800 shares of Zenas BioPharma(NASDAQ:ZBIO), an estimated $5.19 million trade based on quarterly average pricing. ENAVATE Sciences added 157,800 shares of Zenas BioPharm... Full story

Yahoo Finance • 14 days ago

This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares

On February 17, 2026, OrbiMed Advisors reported selling 143,304 shares of Sionna Therapeutics(NASDAQ:SION), an estimated $5.43 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commiss... Full story

Yahoo Finance • 27 days ago

Sionna Therapeutics GAAP EPS of -$0.46

* Sionna Therapeutics press release [https://seekingalpha.com/pr/20419038-sionna-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results] (SION [https://seekingalpha.com/symbol/SION]): Q4 GAAP EPS of -$0.46. * Cash and... Full story

Yahoo Finance • 3 months ago

Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Upgrades: TD Cowen upgraded Ametek (AME) to Buy fr... Full story

Yahoo Finance • 4 months ago

Sionna Therapeutics to Participate in Upcoming December Investor Conferences

WALTHAM, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing no... Full story

Yahoo Finance • 5 months ago

Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference

Phase 1 data of first-in-class NBD1 stabilizers, SION-719 and SION-451, demonstrated they were generally well tolerated and exceeded desired pharmacokinetic targets New preclinical data show that NBD1 stabilizers restored the half-life of... Full story

Yahoo Finance • 5 months ago

Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis

SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosis Topline data expected in mid-2026 WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage... Full story

Yahoo Finance • 6 months ago

Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference

WALTHAM, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing no... Full story

Yahoo Finance • 7 months ago

Sionna Therapeutics to Participate in Upcoming September Investor Conferences

WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing no... Full story

Yahoo Finance • 7 months ago

Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis

WALTHAM, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing no... Full story

Yahoo Finance • 8 months ago

Guggenheim reiterates Buy rating on Sionna Therapeutics stock at $45 target

Investing.com - Guggenheim has reiterated its Buy rating and $45.00 price target on Sionna Therapeutics (NASDAQ:SION) following the company’s second-quarter 2025 financial results. According to InvestingPro data, analysts maintain a Stro... Full story

Yahoo Finance • 10 months ago

Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model

Data featured in oral presentation and poster session at 48th European Cystic Fibrosis Conference WALTHAM, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on... Full story

Yahoo Finance • 10 months ago

Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference

WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing nov... Full story

Yahoo Finance • last year

Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Phase 1 MAD dosing completed for SION-451 and final MAD cohort of SION-719 planned; Interim data in healthy volunteers show potential to provide clinically meaningful benefit to CF patients. Topline data anticipated in first half of 2025... Full story

Yahoo Finance • last year

Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference

BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medi... Full story

Yahoo Finance • last year

Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

BOSTON, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medi... Full story